Aadi Bioscience Inc expected to post a loss of 74 cents a share - Earnings Preview

Whitehawk Therapeutics

07/11/2022 18:07

* Aadi Bioscience Inc  AADI.OQ   AADI.O  is expected to show
a
rise in quarterly revenue when it reports  results on November
9. 
    * The Pacific Palisades California-based  company is
expected to
report revenue of $3.771 million, according to the mean estimate
from 4 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Aadi Bioscience Inc
is
for a loss of 74 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aadi
Bioscience
Inc is $46.5​, above​ its last closing price of $12.53. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.74       -0.75      -0.87     Missed  -16
 Mar. 31 2022  -0.71       -0.71      -0.66     Beat    7.3
 Dec. 31 2021  -0.67       -0.98      -0.77     Beat    21.6​
 Sep. 30 2021  -0.66       -0.66      -1.36     Missed  -105
 ​​Jun.        -6.00       -6.00      -1.35     Beat    77.5
 30 2021                                                
 Mar. 31 2021  -1.35       -1.35      -1.35     Met     0​
 Dec. 31 2020  -2.02       -2.02      -1.50     Beat    25.9
 Sep. 30 2020  -2.10       -2.10      -1.80     Beat    14.3
 This summary was machine generated November 7 at 18:07 GMT.  All
figures in US dollars  unless otherwise stated